A double blind, placebo-controlledstudy that looked into the potential effectiveness of topical fluridil for treating male androgenetic alopecia, showing increased anagen to telogen ratios with no reported side effects on libido or sexual performance.
Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.
The release of a study on 5a-reductase inhibitors (finasteride and dutasteride) which showed an increased risk of depression, dementia, decreased libido, and reduced semen load as potential side effects; discussion around other forms of hair loss treatments such as topical minoxidil, RU58841, or opting to accept baldness; and advice to consider professional help for deeper issues related to hair loss.
Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.
The conversation discusses the effectiveness of various doses of Dutasteride in reducing scalp DHT and its impact on hair count. Users shared personal experiences with hair loss treatments, including Dutasteride, Finasteride, and Minoxidil, with one reporting significant hair loss reduction using a combination of oral Dutasteride and topical Minoxidil and Finasteride.